Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16732180 | 0.84 | KMT2A (0.56) | KMT2ALMNAPTGS1PTGS2HKDC1 | |
| SCHEMBL27424998 | 0.83 | ESR1 (0.49) | KMT2APTGS1ALDH1A1 | |
| SCHEMBL1923823 | 0.82 | LMNA (0.52) | KMT2ALMNAPTGS1HKDC1MEN1 | |
| SCHEMBL6174681 | 0.80 | CYP3A4 (0.52) | KMT2ALMNAPTGS1PTGS2HKDC1 | |
| SCHEMBL487424 | 0.79 | KMT2A (0.63) | KMT2ALMNAPTGS1PTGS2MEN1 | |
| SCHEMBL8571791 | 0.78 | KMT2A (0.62) | KMT2ALMNAPTGS1PTGS2MEN1 | |
| SCHEMBL5789506 | 0.78 | KMT2A (0.62) | KMT2ALMNAPTGS1PTGS2MEN1 | |
| SCHEMBL6874324 | 0.78 | KMT2A (0.62) | KMT2ALMNAPTGS1PTGS2MEN1 | |
| SCHEMBL8634836 | 0.78 | KMT2A (0.62) | KMT2ALMNAPTGS1PTGS2MEN1 | |
| SCHEMBL10061860 | 0.78 | KCNA5 (0.50) | KMT2ALMNAPTGS1PTGS2HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405841-B1 | PROCESS FOR PREPARATION OF 2-OXOCARBOXYLIC ACID ESTERS | KURARAY CO (JP) | 2006-08-16 | — | — | EP | disclosed |
| US-6897335-B2 | Process for preparation of 2-oxocarboxylic acid esters | KURARAY CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
| US-20040162441-A1 | Process for preparation of 2-oxocarboxylic acid esters | KURARAY CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
| EP-1405841-A1 | PROCESS FOR PREPARATION OF 2-OXOCARBOXYLIC ACID ESTERS | KURARAY CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162441-A1 | Process for preparation of 2-oxocarboxylic acid esters | HAO2, HACL2, HAO1 | KMT2A 2994/4885LMNA 2246/4885PTGS1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.